Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: former_pgs who wrote (464)	2/24/2005 9:10:53 PM
From: Clarksterh	of 946

If I'm correctly reading Miljenko's original comment (valuation thread #15165), 80-90% of the xyotax administered is recovered in the urine, intact. If the glutamate chains were not severed from the active ingredient, then logically that conjugated form could not have had a therapeutic effect in the patient. From the article: <<In rats, the major route of elimination of [14C]paclitaxel poliglumex was by hepatic clearance and biliary excretion; urinary excretion was a minor route of elimination (Baker, unpublished observations). >> A contradiction. (unless you believe rats and humans metabolize Xyotax very differently) Clark

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next